Edit
Grey Wolf Therapeutics Stage
http://www.greywolftherapeutics.com/Last activity: 29.10.2025
Active
By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
Location: United States, Ohio, Oxford
Employees: 11-50
Total raised: $111.86M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 01.02.2023 | British Pa... | britishpat... |
| - | Canaan Par... | canaan.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.05.2024 | Series B | $50M | - |
| 27.01.2023 | Series B | $49M | - |
| 11.02.2019 | Series A | $12.86M | Andera Par... |
Mentions in press and media 9
| Date | Title | Description |
| 29.10.2025 | Earlybird Health promotes two new partners as firm deepens biotech and analytics focus | Life sciences investor Earlybird Health has promoted Dr. Rabab Nasrallah and Dr. Christoph Massner to Partners. Both new partners have led the firm's strategy across biotech, data-enabled therapeutics and medtech. Earlybird Health, part of ... |
| 23.05.2024 | Grey Wolf Therapeutics Closes $50M Series B Financing Expansion | Grey Wolf Therapeutics, an Oxford, UK-based clinical-stage biotechnology company leveraging antigen modulation therapies, raised $50M in Series B extension funding. The round, which brought the total amount to $99M, was led by ICG’s Life Sc... |
| 23.05.2024 | UK-based Grey Wolf Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders | - |
| 27.01.2023 | British Patient Capital invests $7m in immuno-oncology specialist Grey Wolf Therapeutics | 26 January 2023: British Patient Capital has participated in the $49m Series B funding round of immuno-oncology specialist Grey Wolf Therapeutics as the company looks to begin testing their novel small molecule anti-cancer treatment in the ... |
| 26.01.2023 | Grey Wolf Therapeutics Closes $49M Series B Financing | Grey Wolf Therapeutics, an Oxford, UK-based biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, raised $49M in Series B funding. The round was led by Pfizer Ve... |
| 08.11.2019 | Cambridge companies recognised at industry leading OBN Awards 2019 event | Cambridge companies recognised at industry leading OBN Awards 2019 event 08-11-2019 Cambridge Network members Bicycle Therapeutics and Endomag have been honoured at the 2019 OBN Awards, which celebrate the best of UK life sciences. OBN (UK)... |
| 11.02.2019 | Grey Wolf Therapeutics completes £10 million series A financing with Andera Partners and Canaan | |
| - | Grey Wolf Therapeutics | “By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.” |
| - | Grey Wolf Therapeutics | “By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.” |